Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Tekmira Pharmaceuticals Corporation    TKM   CA87911B2093

TEKMIRA PHARMACEUTICALS CORPORATION (TKM)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Tekmira Pharmaceuticals Corporation : Tekmira to License Technology to Monsanto for Weed Control Research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2014 | 03:00pm CEST
By Everdeen Mason 

Tekmira Pharmaceuticals Corp. agreed to allow agriculture business Monsanto Co. to license use of its proprietary delivery technology, a deal Tekmira says is worth up to $86.2 million.

Tekmira shares shot up 33% in premarket trading following the deal's announcement.

Tekmira, which focuses on RNA interference therapeutics, will provide lipid formulations to Monsanto, which will be used for the latter company's research on new pest, virus and weed control options for agriculture.

The option agreement between the two companies will last four years, and Monsanto will pay Tekmira an option exercise fee for the exclusive right use Tekmira's technology in agriculture. Tekmira said it expects a near term payment of $16.5 million.

Monsanto, which is the largest seed company by sales, has benefited from a long-running farm boom in the U.S. and South America driven by high prices for corn and other commodities.

Write to Everdeen Mason at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
MONSANTO -0.05% 124.68 Delayed Quote.6.82%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEKMIRA PHARMACEUTICALS CO
04/12Arbutus Presents Complementary Results From Preclinical Combination Studies o..
GL
04/11Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform t..
GL
03/28Arbutus to Present HBV Data at 2018 EASL Liver Meeting
GL
03/14Arbutus Announces Corporate Update and Year-End 2017 Financial Results
GL
03/12Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Qu..
GL
02/22Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technolo..
GL
02/15Arbutus Enters Exclusivity Agreement with Roivant Sciences
GL
02/14Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO
GL
02/08Arbutus Consolidates HBV Business Around Warminster, PA Site
GL
01/16Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investme..
GL
More news
News from SeekingAlpha
2015WHO approves rapid test for Ebola 
2015BIOTECH STOCKS : What's Hot, What's Not - As Seen By Market-Makers, Their Client.. 
2015U.S. to pull troops from Ebola zone 
2015SEEKING ALPHA'S BIOTECH WEEKLY : Questioning Gilead, MannKind To Market, And Mor.. 
2015TEKMIRA : Bad Idea Genes 
Financials ($)
Sales 2018 0,86 M
EBIT 2018 -92,5 M
Net income 2018 -94,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 354x
Capi. / Sales 2019 79,6x
Capitalization 303 M
Chart TEKMIRA PHARMACEUTICALS CO
Duration : Period :
Tekmira Pharmaceuticals Co Technical Analysis Chart | TKM | CA87911B2093 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 9,75 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Mark J. Murray President, Chief Executive Officer & Director
Vivek Ramaswamy Chairman
Koert VandenEnden Chief Financial Officer
Peter Lutwyche Chief Technology Officer
Michael J. Sofia Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEKMIRA PHARMACEUTICALS CORPORATION0.00%303
CSL LIMITED14.47%55 642
BIOGEN-15.42%54 858
ALEXION PHARMACEUTICALS-9.83%23 977
GRIFOLS-5.92%17 583
BIOMARIN PHARMACEUTICAL-7.95%14 452